VEGFA - Vascular Endothelial Growth Factor A, also known as or Vascular permeability factor (VPF), is a major signaling growth factor member of the VEGF family, sub-group of the Platelet-Derived Growth Factor (PDFG) proteins, which is characterized by its conserved cystine-knot structure.1 VEGF expression is up regulated in hypoxia and in many types of cancers. Furthermore, VEGF receptors (VEGFR1 and VEGFR2) are also overexpressed in several tumors and studies have shown that high levels of VEGF correlates with poor prognosis.1-8 Inhibition of VEGF mediated angiogenesis signaling pathways have potential in angiogenesis-related disease therapy, this can be achieved by blocking either the circulating VEGF using Anti-VEGF antibodies such as Bevacizumab and Aflibercept5 or by VEGFR-2 inhibition using small molecules such as Gamabufotalin (CS-6) and Arenobufagin.6-8
Synonyms: VEGF-A; VPF; Vascular endothelial growth factor A; Vascular permeability factor
Storage: -20C
Application: The antibody is recommended to use in various immunological techniques, including Immunoblot (~21 kDa). Detection of the VEGF165 band by Immunoblotting is specifically inhibited by the immunogen.
Biochem Physiol Actions: VEGF proteins are involved in angiogenesis and vasculogenesis, they predominantly activate proliferation and survival of endothelial cells and migration in non-endothelial cells.1VEGFA have several isoforms due to alternative splicing mainly at exons 6-8. The VEGF exon 8 splicing isoforms are divided into two groups, the "pro-angiogenic" VEGFxxxa isoforms considered to be activators of proliferation, survival and angiogenesis and the VEGFxxxb isoforms that are considered as "anti-angiogenic".2